C-reactive Protein Testing Market– By Product (Instruments, Kits & Reagents), Assay Type (CLIA, ELISA, Immunoturbidimetric Assay), Detection Range (Hs-CRP, Standard CRP), Application, (Cardiovascular Diseases, Infectious Diseases), End-use & Forecast, 2024 – 2032

C-reactive Protein Testing Market Size

C-reactive Protein Testing Market size was valued at around USD 3.2 billion in 2023 and is expected to reach around USD 4.4 billion by 2032 at a CAGR of 3.9% from 2024 to 2032. The growth of the market is being driven by the rising prevalence of chronic disorders coupled with an increased demand for CRP testing for the effective diagnosis and management of these conditions.

Chronic conditions like rheumatoid arthritis, cardiovascular diseases, and diabetes necessitate regular monitoring and management, which is facilitated by CRP testing. The rise in these chronic conditions has led to a greater reliance on CRP tests for early detection and ongoing management. For instance, according to the World Health Organization (WHO), as of 2023, chronic diseases are responsible for 71% of all deaths globally, underscoring the critical need for effective diagnostic and monitoring tools. This surge in chronic disease prevalence is thus fueling the demand for CRP testing on a global scale.
 

C-reactive protein (CRP) testing measures the level of C-reactive protein in the blood, which is produced by the liver in response to inflammation. Elevated CRP levels can indicate acute or chronic inflammation due to various conditions such as infections, autoimmune diseases, and cardiovascular diseases. The test helps diagnose and monitor inflammatory disorders, assess the severity of infections, and evaluate the risk of heart disease.
 

C-reactive Protein Testing Market Trends

Technological innovations in testing technologies enhancing the accuracy, speed, and convenience of CRP testing, making it a more accessible and reliable tool for diagnosing and monitoring inflammatory conditions, and driving the market growth.
 

• Recent developments in point-of-care testing (POCT) technology allow for rapid, on-site CRP testing with immediate results. These portable medical devices are especially useful in emergency settings and remote locations, providing quick diagnostic insights without the need for specialized laboratory equipment.
   
• Additionally, advanced automated analyzers have improved the efficiency and throughput of CRP testing in clinical laboratories. These systems can process multiple samples simultaneously with high precision, reducing turnaround times and minimizing human error.
   
• Furthermore, innovations in high-sensitivity CRP assays enable the detection of very low levels of CRP, which is crucial for assessing cardiovascular disease risk. Newer hs-CRP tests offer improved sensitivity and specificity, making them valuable for early detection and preventive healthcare.
   
• Moreover, emerging CRP testing solutions are increasingly being integrated with digital health platforms and electronic health records (EHRs). This integration allows for seamless data management and real-time monitoring, enhancing patient care and facilitating better clinical decision-making. These technological innovations enhance the effectiveness and accessibility of CRP testing, driving market growth globally.
   

C-reactive Protein Testing Market Analysis 

Based on product, the market is categorized into instruments, kits and reagents. The kits and reagents segment dominated the market with the revenue of 2 billion in 2023.
 

• Kits and reagents are versatile and can be used with various instruments and platforms, making them suitable for different types of CRP assays, such as chemiluminescence immunoassay (CLIA), enzyme-linked immunosorbent assay (ELISA), and immunoturbidimetric assay. This adaptability increases their utilization across diverse clinical settings.
   
• Moreover, many CRP testing kits are designed to be user-friendly and provide rapid results, which is crucial in clinical settings where timely decision-making is essential. The convenience and efficiency of these kits contribute to their preference over more complex and time-consuming methods.
    

Based on assay type, the C-reactive protein testing market is categorized into chemiluminescence immunoassay (CLIA), enzyme-linked immunosorbent assay (ELISA), immunoturbidimetric assay, and other assay types. The immunoturbidimetric assay segment anticipated to dominate the market with the revenue of 1.6 billion during forecast period.
 

• Immunoturbidimetric assays are more affordable compared to other assay types like chemiluminescence immunoassay (CLIA) and enzyme-linked immunosorbent assay (ELISA). This cost-effectiveness makes them an attractive option for a wide range of healthcare providers, including smaller clinics and laboratories with limited budgets.
   
• Additionally, these assays are known for their rapid processing time and efficiency. They can deliver quick results, which is crucial in clinical settings where timely decision-making is necessary. The faster turnaround time helps in promptly diagnosing and managing inflammatory conditions, hence contributes to their segmental growth.
   

Based on detection range, the C-reactive protein testing market is categorized into high-sensitivity CRP (Hs-CRP), and standard CRP. The standard CRP segment dominated the market by obtaining market share of around 54% in 2023.
 

• Standard CRP tests are widely used across a broad range of clinical applications. They are employed in the diagnosis and monitoring of various inflammatory and infectious diseases, as well as chronic conditions. This versatility makes them a staple in routine clinical practice.
   
• Moreover, Hs-CRP tests are necessary for detecting low levels of CRP in cardiovascular risk assessment, standard CRP tests are adequate for diagnosing and monitoring acute infections, inflammatory diseases, and other conditions where higher levels of CRP are present, hence contributes to its segmental growth.  
   

Based on application, the C-reactive protein testing market is categorized into cardiovascular diseases, infectious diseases, chronic inflammatory diseases, and other applications. The cardiovascular diseases segment anticipated to dominate the market with the revenue of 1.7 billion during forecast period.
 

• Cardiovascular diseases are among the leading causes of morbidity and mortality worldwide, affecting a large patient population. The high prevalence of cardiovascular conditions generates substantial demand for CRP testing, both for initial risk assessment and ongoing monitoring.
   
• Additionally, CRP testing has become integrated into routine cardiac care, particularly in the management of patients with existing cardiovascular diseases. Regular monitoring of CRP levels helps in assessing the efficacy of treatments and guiding therapeutic decisions, contributing to its dominance in this segment.
   

Based on end-use, the C-reactive protein testing market is categorized into hospitals and clinics, diagnostic laboratories, and other end-users. The hospitals and clinics segment dominated the market with a revenue of around USD 1.6 billion in 2023.
 

• In hospitals and clinics, CRP testing is often performed to support immediate clinical decision-making. Rapid results from CRP tests can help physicians quickly diagnose and manage conditions such as infections, inflammatory diseases, and cardiovascular events, which are critical in acute care settings.
   
• Moreover, hospitals and clinics serve a multidisciplinary patient population, including those in departments like internal medicine, cardiology, infectious diseases, and rheumatology. The cross-departmental use of CRP testing further amplifies its demand for these facilities.
   

North America C-reactive protein testing market accounted for USD 1.2 billion in revenue in 2023 and is predicted to witness substantial market growth over the analysis timeline.
 

• North America has a high prevalence of chronic diseases such as cardiovascular diseases and diabetes. This increased incidence drives the demand for C-reactive protein (CRP) testing, as CRP levels are commonly monitored to assess inflammation related to these conditions.
   
• Additionally, the presence of advanced healthcare facilities and widespread access to diagnostic technologies in North America supports the growth of the CRP testing market. High adoption rates of innovative diagnostic tools and a focus on early disease detection contribute to increased CRP test utilization.
   

The U.S. C-reactive protein testing market is anticipated to reach USD 1.4 billion by 2032, driven by numerous factors.
 

• There is a growing emphasis on preventive healthcare in the U.S., which drives the demand for CRP testing as part of routine health check-ups and preventive screenings. Healthcare policies promoting preventive measures and early diagnosis further bolster market growth.
   
• Additionally, the awareness and education surrounding inflammatory diseases and their links to various health conditions have increased. This heightened awareness encourages both patients and healthcare providers to utilize CRP testing for better management and monitoring of inflammatory conditions.
   

The C-reactive protein testing market in UK is expected to experience significant and promising growth from 2024 to 2032.
 

• The UK's healthcare system, guided by the National Health Service (NHS), incorporates regular screening and monitoring of inflammatory markers like CRP. NHS guidelines and recommendations for managing chronic diseases contribute to the steady demand for CRP testing.
   
• Additionally, the increasing elderly population in the UK, who are more susceptible to inflammatory diseases and chronic conditions, drives the need for CRP testing. As the aging population grows, so does the requirement for diagnostic tools to monitor inflammation and related health issues.
   

Japan C-reactive protein testing market is anticipated to witness lucrative growth between 2024 – 2032.
 

• The country's focus on technological innovation and its strong emphasis on healthcare research and development contribute to the growth of the CRP testing market. Advanced diagnostic technologies and integration of CRP testing into routine clinical practices drive market expansion.
   
• Additionally, the Japanese government’s health initiatives and comprehensive screening programs aim to address chronic diseases and promote early detection. These programs often include CRP testing to monitor inflammation and manage health conditions, thus supporting market growth.
   

C-reactive Protein Testing Market Share

The C-reactive protein testing industry is characterized by the presence of several established and emerging players that offer a variety of products across the globe. The market players compete based on factors such as product quality, innovation, regulatory compliance, customer service, and pricing strategies.

C-reactive Protein Testing Market Companies

Prominent players operating in the C-reactive Protein Testing industry include:

• Abbott
• Agilent technologies
• Aidian
• Boditech Med, Inc.
• Creative diagnostics
• CTK Biotech
• Danaher
• DxGen Corp
• F. Hoffmann-La Roche Ltd.
• Getein Biotech, Inc.
• Goldsite diagnostics
• HORIBA, Ltd
• Laboratory Corporation Of American Holding
• LumiraDX
• Merck KGaA
• Optibio co., Ltd
• Randox Laboratories Ltd.
• Siemens Healthineers AG
   

C-reactive Protein Testing Industry News:

• In January 2022, LumiraDx announced that its C-reactive protein (CRP) Test achieved CE Marking. The LumiraDx CRP Test is a small, portable, fully automated, microfluidic immunoassay test used for the quantitative determination of C-reactive protein with results within four minutes. This approval improved the company’s product range and increased its reputation in the market.
• In September 2021, HORIBA UK Limited launched its new generation Microsemi CRP point-of-care haematology analyser. This launch increased the company’s competitiveness in the market.
   

C-reactive protein testing market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 to 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Instruments
• Kits and reagents

Market, By Assay Type

• Chemiluminescence immunoassay (CLIA)
• Enzyme-linked immunosorbent assay (ELISA)
• Immunoturbidimetric assay
• Other assay types

Market, By Detection Range

• High-sensitivity CRP (Hs-CRP)
• Standard CRP

Market, By Application

• Cardiovascular diseases
• Infectious diseases
• Chronic inflammatory diseases
• Other applications

Market, By End-Use

• Hospitals and clinics
• Diagnostic laboratories
• Other end-users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of Middle East and Africa